Characteristics of adverse events of endocrine therapies among older patients with breast cancer.

Naoko HonmaMasujiro MakitaShigehira SajiTetuo MikamiHideaki OgataRie HoriiFutoshi AkiyamaTakuji IwaseShinji Ohno

Published in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2019)

Among patients ≥ 70 years old, many symptoms were significantly more frequent/severe with AIs than with SERMs, compared with those aged 56-69, which suggests a difference in the profile of adverse events according to the type of endocrine therapy and the patient's age. It is important to consider the benefits and risks of each treatment to optimize endocrine therapy for older patients.

Keyphrases

early onset
stem cells
human health
combination therapy
physical activity
sleep quality
mesenchymal stem cells
replacement therapy